Extending Our Research Programme with the University of Sussex

Our research collaboration with the University of Sussex commenced in June 2020 with the opening of our dedicated laboratory within the School of Life Sciences. After extensive preparation by the team, we successfully gained our Schedule 1 controlled drugs licence in February 2021.
113 Botanicals is delighted to announce the renewal of our collaboration agreement with the University of Sussex and the continuation of our sponsorship of the ongoing post-doctoral research programme. We are pleased to be able to expand the remit of this important and exciting project, led by our CTO, Mazin Nicola, to include the following objectives:
Led by our CTO, Mazin Nicola, the objectives of this continued R&D are to:
  1. To optimise the critical parameters of the extraction process in-order to maximise product quality, safety and efficacy.
  2. Investigate effective routes of administration of cannabis-based medicinal products (CBPMs).
  3. Characterise CBPMs in disease models with particular focus on symptoms associated with sleep deprivation and pain relief associated with Parkinson’s Disease and Multiple Sclerosis.
  4. Assess the use of CBPMs in the alleviation of damage to lung tissue caused by inflammation and sepsis resulting from COVID-19 infection.
  5. Develop a robust clinical trial protocol in consultation with relevant patient groups and research-based charities to assess the safety and efficacy of CBPMs and to ensure our approach always maintains a ‘patient first’ focus.
We thank the University of Sussex wholeheartedly for their generous support and professional expertise in the above listed topics.